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he burden of CNS disorders, combined with an increasingly aged population, is one of the key global health 
challenges of our time. Indeed, the World Health Organization has highlighted that up to 1 billion people sufer 
from neurological disorders and those sufering from dementia, currently exceeding 20 million, are expected to 
double every 20 years unless action is taken1. Despite global R&D pharmaceutical spending in brain disorders 
exceeding $140 billion per annum, and its growth set to continue2, early stage drug discovery has serious cost 
implications and high attrition rates, as investigational CNS-leads fail due to the well-known bottleneck in late 
stage clinical trials3. A recent meta-analysis on the clinical success rates of drugs in the development pipeline 
revealed that approximately, only 1 in 10 CNS active compounds eventually meets FDA approval4. he most com-
mon reasons for this level of attrition ranged from inadequate in vitro and in vivo models, to poor drug physico-
chemical properties and eicacy, in addition to in vivo toxicity4,5. herefore, new technologies and methodologies 
for characterising CNS active compounds are a priority if healthcare and well-being are to be improved.
Early stage drug development heavily relies upon in vitro cultures, with neurons grown on coverslips prior to 
drug screening. However, when combined with plate-based high-throughput instrumentation, there is oten fail-
ure in monitoring synaptic activity typical of the in vivo microenvironment6,7, as only single neuronal networks 
can be investigated with this approach. Standard laboratory in vitro techniques used to screen for CNS active com-
pounds include electrophysiological assays, such as patch clamping and multi-electrode arrays (MEAs), as well 
as optical calcium (Ca2+) imaging techniques. Whilst the use of patch clamping provides exceptional temporal 
resolutions of neuronal activity in response to drug application8–10, it is time consuming, requires specialist train-
ing and is low throughput. Alternatively, cells can be grown across MEA substrates to obtain electrophysiological 
readouts across an entire neuronal network11, however the likelihood of a cell interfacing with a single electrode is 
low, and recordings may not detect subthreshold readings which would indicate if either excitatory or inhibitory 
signals were received12. he use of Ca2+ imaging instead allows repeated acute recordings of cellular activity with-
out inducing toxicity, but the technique is typically constrained to low temporal resolutions. However, it provides 
single-cell spatial resolution over a wide cultured area and can be used to carry out cost-efective investigations 
of synaptic activity13.
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he use of microluidic procedures to model in vitro pathological conditions has gradually increased over the 
past decade, due to the level of control and manipulation available over the cellular microenvironment and exper-
imental conditions14,15. hese systems also show potential for use as drug discovery platforms, taking advantage 
of engineering techniques to facilitate high-throughput pharmacological assays, either by device design or the 
incorporation of perfusion systems to wash on/of multiple compounds16–19. Further advantages of microluidic 
systems include low production costs, reduction in drug sample volumes, and the ability to analyse multiple, envi-
ronmentally isolated but functionally connected cultures20–23, a degree of experimental capability that is lacking in 
conventional culturing techniques. Additionally, the transparent nature of poly-dimethylsiloxane (PDMS) based 
microluidic devices make them ideal for carrying out both quantitative and qualitative pharmacological assays 
via Ca2+ imaging techniques20,21,24. As such, microluidic systems are versatile tools that are well suited to perform 
pharmacological research15,20,21,25–27.
In this study, we present a microluidic system that integrates computer-controlled perfusion of multiple com-
pounds with Ca2+ imaging techniques to provide a platform for the characterisation of CNS active compounds. 
he novelty of this approach is its ability to simultaneously detect direct responses within a primary hippocampal 
culture to repeated drug applications whilst monitoring the consequent synaptic activity in an adjacent, func-
tionally connected but environmentally isolated hippocampal culture. Hence, the proposed platform provides a 
novel, miniaturised solution amenable to CNS drug discovery, ofering the ability to simultaneously screen both 
the direct efects of compounds on cells, as well as how such drugs inluence communication between synaptically 
connected cultures.

Ǥ Microluidic devices were fabricated using photo/sot-lithography 
techniques as described previously20, comprising of an array of microchannels between two culture chambers 
that are luidically addressable via inlet/outlet wells. In brief, a two-layer microluidic master was fabricated by 
spinning SU8 photoresist (3000 series, Microchem, US) onto a silicon wafer. he irst layer (SU8 3010) created 
the microchannels (7 µm thick, 10 µm wide and 450 µm long), and the second layer (SU8 3035), the culture cham-
bers (80 µm thick, 2 mm wide and 9.5 mm long). he silicon master was then silanized by vapour deposition of 
1 H,1 H,2 H,2H-perluorooctyl-trichlorosilane (Sigma Aldrich, UK) for 1 hour. PDMS was poured onto the mas-
ter at a 10:1 ratio of base to curing agent and degassed in a vacuum desiccator prior to curing at 80 °C for 3 hours. 
he PDMS layer was then peeled of the master and devices were cut to the desired size, with the inlet/outlet wells 
(4 mm diameter) of each chamber created using a biopsy punch. Microluidic devices were inally cleaned and 
irreversibly bonded to coverslips using oxygen plasma. Bonded devices were UV sterilised for 15 minutes, treated 
with poly-L-lysine solution (PLL, 10 µg ml−1) for 1.5 hours, and washed with sterile Neurobasal-A medium.
ƪǤ Using dual culture chamber microluidic devices, a steady low rate in 
a single culture chamber (perfused chamber; with a constant low rate Qch) was achieved by creating a constant 
hydrostatic pressure diference between its inlet and outlet wells. he adjacent culture chamber (naïve cham-
ber) was kept in almost static luid conditions. Polytetraluoroethylene (PTFE) tubing (0.255 mm inner diameter, 
~700 mm length, Cole-Parmer, UK) connected glass syringes to needle ports created through the PDMS wall 
of the inlet-outlet wells of the perfused chamber, and the luid was actuated using syringe pumps (AL-1000, 
World Precision Instruments). Up to four syringe pumps were connected to one inlet well of the device for luid 
injection, with only one of these syringe pumps active at any given time and set to a constant low rate (QI−P). 
Two further syringe pumps were used for luid withdrawal at constant low rates, one connected to the inlet 
(QI−W) and one to the outlet (QO−W) well, respectively (Fig. 1a). Syringe pumps were computer-controlled via an 
in-house developed MATLAB (R2015a) program and ensured reliable activation/deactivation of each low rate 
at the desired times. At the beginning of the assay, the following conditions were set to achieve a steady low rate 
in the perfused chamber (QCh):
> > >− − −Q Q Q (1)I P I W O W
− = =− − −Q Q Q Q (2)I P I W Ch O W
hese set of equations give rise to a self-adjusting hydrostatic pressure between the inlet and outlet wells of the 
perfusion chamber that reaches quickly a dynamic equilibrium. On/of alternation of the injection syringe pumps 
was only used to perfuse diferent solutions in the chamber. Due to the module of the low rates in Eq. 1, a rapid 
exchange of the luid solution in the inlet well was obtained without afecting its hydrostatic pressure and leading 
to a prompt injection of the new luid solution into the chamber. he time to completely exchange a perfusate in 
the well was directly proportional to the inlet well’s hydraulic retention time (HRT), where the luid volume of 
the well (VI−well) was replaced under a steady low rate, resulting in HRT ≈ VI−well / QI−P (estimated at ~25 sec-
onds for the current setup). herefore, for a given steady low rate (QCh) in the perfusion chamber with a deined 
cross-section (SCh), the time (Tex) taken for the full perfusate (i.e. 100% concentration) to travel a distance L 
within the chamber from the inlet well can be estimated as:
≈ +
×
T HRT
S L
Q (3)
ex
Ch
Ch
Under these conditions, Tex is the time required for the complete exchange of solution in the inlet well and the 
subsequent arrival of the new solution at an arbitrary point that is a distance L away from the inlet well within 
the perfused chamber. When L is half the length of the culture chamber, Tex is estimated at ~35 seconds for the 
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current device geometry. To avoid cross contamination between the perfused and naïve chambers, the initial vol-
ume of luid in the wells connecting the naïve and perfused chambers were adjusted to 50 µl/well and 10 µl/well, 
respectively. his established a hydrostatic pressure gradient across the array of microchannels that was main-
tained throughout the assay. Considering the ratio between the hydraulic resistance of the microchannel array 
and culture chambers20, the hydrostatic pressure gradient resulted in the formation of a negligible low of vehicle 
from the naïve to the perfused chamber that did not inluence the perfusion protocol.
he robustness of this perfusion model was validated experimentally using calcein as a luorescent marker 
(Fig. 1b,c). Non-cultured microluidic devices were connected to the perfusion setup, delivering deionised (DI) 
water through the culture chamber at a steady low rate (4 µl min−1), with three other syringes primed with calcein 
(50 µM in DI water). Devices were then transferred to an inverted microscope (Axio Observer A1, Zeiss) using 
a 2.5× objective and the ield of view was set to span an area that monitored both the microchannel array and 
the culture chambers. Recordings were carried out using an EMCCD camera (LucaR, Andor Technologies) at a 
frame rate of 2.0 Hz and an exposure time of 0.4 seconds. Time-lapsed images were obtained using Andor SOLIS.
A single region of interest (ROI) was selected for the naïve and perfused culture chamber to obtain mean luo-
rescent readouts on either side of the microchannel array in response to calcein perfusions. he raw data (as mean 
value of the ROI) obtained from individual devices was then scaled using the following equation:
Figure 1. Development and characterisation of the microluidic perfusion system. (a) Schematic representation 
of a dual chamber microluidic device with inlet/outlet needle ports for the direct perfusion/withdrawal of luid 
in/from the wells. Computer-controlled syringe pumps were used for luid injection and withdrawal. (b) A 
representative image showing absence of cross contamination in the naïve chamber and microchannels during 
perfusion of calcein (50 µM) in the perfused chamber (dashed lines indicate the microchannel array separating 
the perfused chamber from the naïve chamber). (c) Fluorescent proiles in the perfused (c1) and naïve (c2) 
chambers, respectively upon repeated delivery of calcein solution from 3 diferent pumps. his demonstrated a 
lack of cross-contamination between the chambers and the robustness of the perfusion protocol (n = 9 devices). 
Data is expressed as mean ± S.E.M. (one-way ANOVA with post-hoc Tukey’s test. ***Denotes P < 0.001, relative 
to baseline readings).
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=
−
−
f x
x
( )
( min)
(max min) (4)
Where x is the mean raw luorescent data of each time trace/ROI (sampled at 2 Hz) and min and max are the 
absolute minimal and maximal mean luorescent intensity values. Processed data from separate recordings across 
multiple devices were then averaged.
Ǥ Primary hippocampal cultures were prepared as described previously8,20,28. 
Briely, Sprague Dawley rat pups (1–2 days old) were killed via cervical dislocation, in accordance with the UK 
Home Oice guidelines. he brain was then removed, hippocampi dissected out and placed in dissection solution 
containing (in mM) NaCl 6.78, KCl 0.40, NaHCO3 2.18, NaH2PO4 0.16, MgSO4 0.15, glucose 4.5, CaCl2 0.22. he 
hippocampi were then incubated for 20 minutes in papain solution (1.5 mg ml−1; Sigma Alrdich, UK) diluted 
in dissection solution. he tissue was then dissociated via trituration in bovine serum albumin solution (BSA; 
10 mg ml−1 in dissecting solution; Sigma Aldrich, UK), the cell solution was then spun down at 2000 rpm for 
2 minutes and re-suspended in 1 ml of supplemented Neurobasal-A medium (L-glutamine 2 mM, B27 2% v/v; 
Life Technologies, UK) at a concentration of 5 × 106 cells ml−1. Cells were introduced into either one or both 
chambers of the device (~2.5 × 104 cells per inlet well) as required and incubated for 15 minutes before inlet/outlet 
wells were illed with 50 µl of supplemented media. Devices remained in a humidiied incubator for up to 14 days 
in vitro (DIV) prior to experimentation, with media replenished every 2–3 days.
ơǤ Hippocampal cultures (12–14 DIV) in microluidic 
devices were washed with a HEPES based external solution (HBS, containing, in mM: NaCl 140, KCl 5, MgCl2 
2, HEPES 10, D-glucose 10, CaCl2 2; pH = 7.4; 310 mOsm). Cultured devices were connected to the perfusion 
setup and volumes adjusted to 50 µl and 10 µl in the wells connected to the naïve and perfused chamber, respec-
tively. Subsequently, multiple values of steady-state low rates (in a range of 0.4–10 µl min−1) were sustained in the 
perfused chambers for an hour and the cells were then stained for live/dead assessment. As control experiments, 
devices were also either let in stasis for an hour (Static t1h, with all wells containing 50 µl) or were stained for cell 
death immediately ater removal from the incubator (Static t0h). Cultures were treated with propidium iodide (PI, 
20 µM) & Hoechst (4.5 µM) made up in HBS for 30 minutes, then washed and allowed to recover for 15 minutes. 
Devices were then transferred to an inverted microscope (Axio Observer Z1, Zeiss), with bright-ield and luores-
cent images for each culture chamber captured using a 10× objective and a cooled CCD camera (AxioCam MRm, 
Zeiss), analysed with ZEN 2012 (Blue edition, Zeiss). Dead cells were identiied by the co-staining of Hoechst and 
PI, whilst living cells were identiied by the sole staining of Hoechst.
Ǥ Microluidic hippocampal cultures (12 DIV) were ixed and stained to identify 
neuronal and glial populations. Briely, using a previously established protocol20, cultures were washed with 
phosphate bufered saline solution (PBS) and ixed with ice cold paraformaldehyde (4% w/v, 10 min), followed 
by ice cold methanol treatment (100%, 10 min). Cultures were then washed with PBS and permeabilised with 
Triton-X100 (0.01%, 10 min), prior to treatment with blocking solution (in % w/v; foetal bovine serum 5, BSA 1) 
for 1 hour to prevent non-selective binding. Cultures were incubated at 4 °C overnight with primary antibodies 
β-III-Tubulin (Life Technologies, UK; neuronal speciic cytoskeleton marker; 1:500 dilution), glial ibrillary acidic 
protein (GFAP; Sigma Aldrich, UK; astrocytic marker; 1:500 dilution), synaptophysin (Millipore, UK; synaptic 
vesicle marker; 1:500 dilution) and MAP2 (Sigma Aldrich, UK; somatodendritic marker; 1:500 dilution). he 
cells were then washed with PBS, and incubated with the relevant luorescently labelled secondary antibodies 
(Alexa 488 or Alexa 555; Life Technologies, UK; 1:200 dilution) for 1 hour at room temperature. Devices were 
then transferred to the inverted microscope (Axio Observer Z1, Zeiss), and imaged using 10×, 20× and 63× 
objectives with a cooled CCD camera (AxioCam MRm, Zeiss). Image analysis was performed using ZEN 2012 
(Blue edition, Zeiss).
Ǥ Data acquisition. Ca2+ imaging was performed on cultures using techniques described 
previously8,20,29. Briely, microluidic cultures (10–14 DIV) were loaded with the luorescent calcium sensitive 
dye Fluo-4-AM (5 µM in HBS for 1 hour at room temperature) and washed with HBS (vehicle) before being 
transferred to an inverted microscope (Axio Observer A1, Zeiss). Devices were then connected to the perfusion 
setup, delivering HBS at a steady low rate (4 µl min−1). hree other syringe pumps, primed with either glutamate 
(0.01–1 mM), glutamate antagonists (NBQX 20 µM, DL-AP5 100 µM, (R,S)-MCPG 500 µM) or glutamate (3 µM) 
in the presence of glutamate antagonists, were used to perfused drugs of interest at a steady low rate of 4 µl min−1. 
Syringe pumps were primed with glutamate (3 µM), the Na+ channel blocker tetrodotoxin (TTX, 1 µM) or gluta-
mate in the presence of TTX and the solutions were perfused at a steady low rate of 4 µl min−1. Devices used to 
generate a glutamate concentration response curve were randomly assigned three separate glutamate concentra-
tions that were perfused in order of increasing concentration. Simultaneous recordings of Ca2+ transients in the 
two environmentally isolated, independent cultures were obtained with a cooled EMCCD camera (LucaR, Andor 
Technologies) using either a 5× or 10× objective, at a frame rate of 2.0 Hz and exposure time of 0.4 s. L-glutamic 
acid (Tocris Bioscience, UK), the glutamate receptor antagonists (NBQX, DL-AP5 & (R,S)-MCPG; Abcam, UK) 
and tetrodotoxin (TTX citrate; Abcam, UK) were made up as 1000× stock solutions and diluted to inal con-
centrations in vehicle solution on the day of experimentation. Time-lapse images were processed and analysed 
using Andor SOLIS, MATLAB (R2015a), and BioGraph (V2.5.6; J. Dempster, University of Strathclyde). As is 
standard, glutamate receptor antagonists or TTX were perfused during the resting period following the irst gluta-
mate perfusion and during the subsequent glutamate application to determine their efects on glutamate-induced 
Ca2+ transients. At the end of each experiment, the perfusion was stopped and KCl (25 mM inal concentration) 
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was applied to each chamber. Cells that did not elicit an immediate and sustained increase in luorescence were 
excluded from analysis (see Supplementary Fig. S1).
Analysis. Regions of interest (ROI) were obtained from individual cell somas and the mean luorescent intensity 
per ROI per frame was used to create a graphic readout of neuronal Ca2+ activity, with each cell’s response trace 
normalised to the basal value for each recording. To produce a concentration response curve, the mean peak 
magnitudes obtained from increasing glutamate concentrations were normalised to the mean peak magnitude 
obtained from the highest glutamate application (1 mM) and the concentration response curve generated using 
the Hill equation:
=
+ ( )
y
R
1
,
(5)
Max
x
EC
n
50
where RMax = maximum response observed, EC50 = efective concentration at which 50% maximum response 
is obtained, and n = Hill coeicient. Otherwise, changes in neuronal activity in response to indirect stimulation 
from the directly perfused neural network were identiied by the automated counting of Ca2+ events. he signals 
of each neuron obtained over the course of the assay were stitched together, iltered (moving average ilter, win-
dow size 11) and normalised to the irst 24 frames of the baseline recording. Events were counted on the basis of 
signiicant increases in luorescence exceeding 7 standard deviations of the median baseline luorescence, occur-
ring within a moving window of 10 seconds. his provided the number of events taking place per neuron during 
both the basal period and glutamate perfusion of each recording, with results normalised to time and the indirect 
activity expressed as events/neuron/minute (ENM).
Ǥ All data is presented as mean ± S.E.M. using bar/scatter graphs and results compared using paired 
student’s t-tests, unpaired t-tests or one-way ANOVA with Tukey’s post-hoc comparison as appropriate, with 
diferences considered signiicant when P < 0.05, or treated otherwise as non-signiicant (ns).

Ǥ To assess the reproducibility of consecutive 
drug applications using the proposed system, initial experiments were performed using calcein to visualise per-
fusion performance and results conirmed a close match with the predicted low behaviour (equations 1–3). he 
protocol developed produced a stable luorescent plateau for the intended duration of perfusion (~30 seconds), 
with increasing (~35 seconds) and decreasing (~45 seconds) transients for all experiments (Fig. 1). Importantly, 
the absence of cross contamination between the two culture chambers was experimentally conirmed, demon-
strating their luidic isolation.
Having validated the robustness of the perfusion protocol, the efect of shear stress on the health of perfused 
hippocampal cultures (12–14 DIV) was examined (Fig. 2) to determine an optimal low rate for the pharma-
cological study. As a benchmark, live/dead imaging was carried out on microluidic cultures immediately ater 
being removed from the incubator, with live cells accounting for 73.8 ± 0.01% (n = 3 devices, each device from a 
separate culture) of the total cell population (Fig. 2b). However, this decreased to 54.1 ± 0.9% (n = 6 devices from 
3 cultures; P < 0.001, static t0h vs static t1h) of the total cell population when the devices were let at room temper-
ature under static conditions for an hour. In contrast, constant perfusion at room temperature, with low rates 
ranging from 0.4–10 µl min−1 (n = 3 devices, each device from a separate culture), revealed varying efects on cell 
viability ater an hour, with live cells accounting for 72.6 ± 1.6% (P < 0.001 vs static t1h) of the total cell popula-
tion at the optimal low rate of 4 µl min−1 (Fig. 2b). Furthermore, the health of the directly perfused cultures was 
closely matched by that of the non-perfused naïve culture across all experimental conditions (non-signiicant, 
P > 0.05). Given these results, a low rate of 4 µl min−1 was used for the remainder of this study. Finally, microlu-
idic cultures were stained for β-III-Tubulin, GFAP and synaptophysin revealing that only neuronal, but not astro-
cytic processes, were able to traverse across the microchannel array to the adjacent chamber and that synapses 
were formed both within and outside the microchannels (see Supplementary Fig. S2). Collectively, continuous 
perfusion experiments and immunocytochemistry imaging indicate that synaptically driven functional commu-
nication exists between the two hippocampal cultures, as previously reported20.
Ǥ As proof-of-concept work, to 
demonstrate the system’s ability to carry out pharmacological characterisation of neuroactive compounds, a 
concentration response curve was generated using the excitatory amino acid, glutamate. Perfusion of glutamate 
(10 nM – 1 mM) elicited reversible concentration-dependent increases in intracellular Ca2+ (Fig. 3a), resulting in 
a concentration response curve with an EC50 of 4.7 ± 0.6 µM (Fig. 3b).
Having established that our integrated perfusion system allows the generation of concentration response 
curves, we tested the platforms capability for the pharmacological screening of compounds. To this end, we 
investigated the actions of ionotropic and metabotropic glutamate receptor antagonists NBQX (20 µM), DL-AP5 
(100 µM) and (R,S)-MCPG (500 µM) on glutamate (3 µM)-induced changes in intracellular Ca2+. Repeated gluta-
mate perfusions elicited robust and reproducible increases in intracellular Ca2+ (n = 182 neurons, 4 devices, each 
device from a separate culture; Fig. 4a & b), which were inhibited in the presence of the glutamate antagonists to 
17 ± 2.5% of the response elicited by glutamate alone (n = 219 neurons, 4 devices, each device from a separate cul-
ture; P < 0.001; Fig. 4c & d). In contrast, no signiicant diference in glutamate-induced increases of intracellular 
Ca2+ (n = 551 neurons, 3 devices, each device from a separate culture; Fig. 4e & f) were observed in the presence 
of TTX (1 µM).
www.nature.com/scientificreports/
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Ǥ Having previ-
ously demonstrated functional synaptic connectivity across two environmentally isolated hippocampal cultures 
following a single drug application20, here changes in postsynaptic responses in the naïve chamber were exam-
ined as a consequence of repeated glutamate (3 µM) applications in the directly perfused chamber (Fig. 5, see 
Supplementary Video S1).
During the irst glutamate application, neuronal activity within the naïve chamber signiicantly increased from 
a baseline of 0.16 ± 0.04 ENM to 0.38 ± 0.04 ENM (P < 0.001; n = 222 neurons; Fig. 5b). Consistent with this, the 
second glutamate application also induced a signiicant increase in neuronal activity from 0.17 ± 0.04 ENM to 
0.44 ± 0.04 ENM during glutamate application (P < 0.001). Similarly, the inal glutamate application elicited a 
signiicant increase in activity, from 0.27 ± 0.05 ENM to 0.4 ± 0.05 ENM (P > 0.05). In the presence of glutamate 
antagonists in the perfused chamber, neuronal activity was unaltered in the naïve chamber (Fig. 5c). A signiicant 
elevation in neuronal activity in the naïve chamber was observed following glutamate application in the presence 
Figure 2. Continuous perfusion maintains cell viability between environmentally isolated neural networks. (a) 
Representative images obtained from perfused and naïve cultures which were stained with Hoechst (blue) and 
PI (red) following continuous perfusion experiments for 1 hour. Scale bar = 200 µm. (b) Microluidic neural 
network viability increases in the presence of perfusion with respect to static condition ater 1 hour, with an 
optimal low rate of 4 µl min−1. Data are presented as mean ± S.E.M. with one-way ANOVA with post-hoc 
Tukey’s test performed; n = 21 devices from 4 cultures; ***denotes P < 0.001.
Figure 3. Microluidic hippocampal cultures respond to direct glutamate (G) application in a concentration-
dependent manner. (a) Ca2+ imaging trace representative of a single neuron’s response to perfusion of 
consecutive, increasing concentrations of glutamate (10–14 DIV). NFU = Normalised luorescent unit. (b) 
Concentration response curve for glutamate (10 nm–1 mM) reveals an EC50 = 4.7 ± 0.6 µM. Data is presented as 
mean ± S.E.M (n ≥ 50 neurons per concentration point, curve obtained from 14 devices from 6 cultures).
www.nature.com/scientificreports/
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of glutamate antagonists, from a baseline of 0.19 ± 0.03 ENM to 0.42 ± 0.04 ENM (P < 0.001; n = 350 neurons; 
Fig. 5c. In contrast, baseline activity in the naïve chamber was signiicantly increased from 0.10 ± 0.02 ENM to 
0.22 ± 0.03 ENM (P < 0.01; B1 vs B2; n = 381 neurons; Fig. 5d) with the presence of TTX in the directly perfused 
chamber, whereas glutamate application in the presence of TTX did not induce any further increases in neuronal 
activity in the naïve chamber (Fig. 5d). Finally, in order to conirm that changes in neuronal activity were unidi-
rectional, hippocampal cultures were grown in one chamber only and glutamate perfused in the non-cultured 
chamber. Repeated application of glutamate (3 µM) in the non-cultured chamber resulted in no changes in neu-
ronal activity in the cultured chamber (see Supplementary Fig. S3).
Figure 4. Reproducible glutamate responses are inhibited by glutamate antagonists. (a, c + e) Representative 
Ca2+ imaging traces of neuronal responses to repeated glutamate applications in the absence or presence 
of antagonists or TTX (purple trace: individual neuronal responses; red trace: average response). 
NFU = Normalised luorescent unit. (b) Repeated applications of glutamate (3 µM) revealed a small but 
signiicant reduction in neuronal response during the third glutamate application. (d) he neuronal response 
to glutamate (3 µM) application was reversibly inhibited in the presence of glutamatergic antagonists (NBQX 
20 µM, DL-AP5 100 µM & (R,S)-MCPG 500 µM). (f) he neuronal response to glutamate (3 µM) application 
was not signiicantly afected in the presence of TTX (1 µM). Data are presented as mean ± S.E.M. with one-
way ANOVA with post-hoc Tukey’s test performed; n ≥ 189 neurons per application, from ≥3 devices from ≥3 
separate cultures; *denotes P < 0.05 and ***denotes P < 0.001.
www.nature.com/scientificreports/
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
his study presents the irst successful integration of microluidic perfusion with Ca2+ imaging techniques into a 
platform that allows the pharmacological characterisation of CNS active compounds using primary hippocampal 
cultures. he novelty of this approach is in examining simultaneously both the direct response to drug applica-
tion (i.e. neuronal excitability) and the consequent alterations in neuronal activity in synaptically connected but 
environmentally isolated primary hippocampal cultures (i.e. induced synaptic activity), over customisable and 
repeatable conditions.
In all the experiments, the difusive transport of compounds could be neglected with respect to their con-
vective transport in the perfused chamber and microchannel array, as the Péclet number30 was always >100 
and the Reynolds number was always <1. Absence of cross-contamination between chambers was experimen-
tally conirmed using luorescent imaging and the results were in line with previously established models20,31–33. 
Importantly, interchangeable perfusion of diferent solutions through a single culture chamber was achieved 
without disturbance in the low. his was obtained by rapidly replacing the liquid volume inside the inlet open 
well of the perfusion chamber, selecting low rate values that were much greater than that created in the perfused 
chamber. he open well system, in combination with carefully selected values of the low rates (equations 1–2), 
generated a self-adjusting hydrostatic pressure diference between inlet and outlet wells of the perfused chamber 
that maintained a constant low rate in the perfused chambers for the duration of the experiment. If the low rate 
Figure 5. Repeated glutamate application induces increased neuronal activity in synaptically connected 
hippocampal cultures. (a) Ca2+ imaging traces representative of activity obtained from individual neurons in 
the directly perfused (trace D1) and naïve (traces I1–I3) culture chambers, demonstrating functional synaptic 
communication between independent hippocampal cultures. (b) Signiicant increases in the number of 
neuronal calcium events were observed in the naïve chamber, with respect to the basal (B) activity, in response 
to the three glutamate (G) applications in the perfused chamber. (c) Signiicant increases in the number of 
neuronal calcium events were observed in the naïve chamber, with respect to the basal (B) activity, in response 
to glutamate applications (G) in the absence and presence of glutamate antagonists in the perfused chamber. 
(d) Basal activity in the naïve chamber was signiicantly increased in the presence of TTX in the perfused 
chamber. Further changes in the number of neuronal calcium events were not observed following glutamate (G) 
application in the presence of TTX. Data are presented as mean ± S.E.M. with paired student’s t-test performed; 
n =  ≥ 222 neurons per application, ≥3 devices from ≥3 separate cultures; ns denotes P > 0.05, *denotes 
P < 0.05, **denotes P < 0.01, ***denotes P < 0.001 and #denotes P < 0.05.
www.nature.com/scientificreports/
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assigned to the inlet well had been the same as that of the perfused chamber, then the time taken to completely 
change perfusates would be signiicantly longer (~5 minutes), which highlights the need for the faster low rate at 
the inlet well. his approach enabled a quick luid transition without creating a pulsatile low when exchanging 
bufer and drug solutions. Further improvements to the platform could be made by replacing the syringe pump 
setup with a pressure-driven, valve-controlled perfusion system, thus extending the number of drugs that can be 
tested in the system, as well as reducing the size and number of external instrumentation needed for active low 
control.
Microluidic perfusion has been extensively applied to a variety of cell types and culture conditions, including 
both brain slices and tissue preparations18,34–38. A previous approach has been reported where a single perfusion 
pump was used to exert a negative pressure across an isolated axonal compartment, consequently withdrawing 
drug solution (applied in situ) from a reservoir to modulate synaptic activity and protein expression37. he main 
limitations of that setup were the requirement for regular, manual drug application throughout the experimen-
tal procedure and that the low of perfusate was not selectively applied to an environmentally isolated culture. 
Alternatively, a model for perfusion has also been described in which neural networks were continuously per-
fused with automated pumps for up to 70 days38, with the cells grown on a microelectrode array within a micro-
scope onstage incubator. Whilst constant simultaneous morphological imaging and electrophysiological readout 
of neuronal activity was monitored over weeks, providing exceptional spatiotemporal resolutions, the protocol is 
time and resource heavy. Interestingly, these reports have shown that continuous perfusion alters synaptic activity 
and may be beneicial to the health of primary neuronal cultures34–36. Previous reports have shown how 2D vs 3D 
cultures, co-culture conditions and shear stress may inluence gene expression, production/transport/removal of 
nutrients and molecular secretions39–42. Our indings suggest that an optimal steady low rate confers neuropro-
tective properties not only to a single perfused primary culture, but also to an adjacent, synaptically connected 
culture. Recently, we have revealed evidence of neuroprotection against spreading toxicity between neighbouring 
synaptically connected but environmentally isolated hippocampal cultures21, and previous studies have proposed 
suppression of excitotoxicity via interneurons in response to mechanically-induced astrocytic release of ATP43–45. 
However, the exact mechanisms underlying this observation in the present study remain unclear.
Ca2+ imaging is a powerful and cost-efective technique that can be used to provide optical readouts of both 
spontaneous and induced cellular activity8,29,46. When combined with the precise spatial and temporal luid low 
control achieved using microluidic systems, high-throughput and miniaturised assays can be performed. Whilst 
neuropharmacological studies have used Ca2+ imaging to perform high-throughput pharmacological analy-
sis47–50, they are either limited in their ine control of stimulus delivery or oten require user intervention to per-
form in situ drug delivery. Furthermore, such conventional systems, which integrate Ca2+ imaging techniques to 
observe neuronal excitability following compound delivery, lack neighbouring environmentally isolated cultures, 
thus limiting the understanding of a drug’s efect on the synaptic connectivity between cultures.
In the present study, we demonstrate proof-of-concept analysis of both neuronal excitability and consequent 
synaptic connectivity. First, a concentration response curve was generated by obtaining reproducible responses to 
a range of glutamate concentrations, revealing an EC50 of 4.7 µM, which compares well to that reported in the lit-
erature51–53. Additionally, the neuronal response to glutamate perfusion in the absence or presence of glutamater-
gic receptor antagonists was examined, revealing reversible inhibition of glutamate-induced transient increases in 
intracellular Ca2+. hese assays highlight that the microluidic perfusion platform described here can be utilised 
for the pharmacological proiling of CNS active compounds. Furthermore, our miniaturised system shows for the 
irst time, repeatable assessment of induced network synaptic activity in addition to pharmacological proiling of 
directly applied compounds in a microluidic format. Indeed, neuronal activity in the naïve hippocampal culture 
was increased in response to multiple glutamate applications but, strikingly, this led to an increased level of basal 
neuronal activity prior to the inal glutamate application. Whilst the inal glutamate application still induced an 
increase in neuronal activity with respect to baseline, repeated synaptically driven signalling appears to induce 
an excited state of activity in the naïve culture, which gradually becomes resistant to further stimulation. his 
observation mimics the increased responsiveness of neurons that undergo synaptic plasticity54 and in this case, 
increased responsiveness similar to that observed in long term potentiation (LTP). Whilst we have not probed the 
underlying mechanisms in the present study, these results are in line with previous studies in which LTP has been 
investigated in cultured hippocampal neurons using both electrophysiological and Ca2+ imaging techniques55–57. 
Basal neuronal activity within the naïve chamber was unaltered in the presence of glutamate antagonists whereas 
increases were observed following glutamate application in their presence. Given that glutamate-induced Ca2+ 
responses in the perfused chamber were signiicantly reduced, but not abolished, in the presence of the antag-
onists, the increases in the naïve chamber are likely to be induced via the residual responses observed in the 
perfused chamber. In contrast, basal activity in the naïve chamber was signiicantly enhanced in the presence of 
TTX in the perfused chamber. Given that our experiments, in which cultures were grown in one chamber only, 
revealed that the glutamate-induced increase in neuronal activity is unidirectional, this result indicates that TTX 
application in the perfused chamber may be impairing an inhibitory tone that controls neuronal activity within 
the naïve chamber. As primary hippocampal cultures grown under our experimental conditions contain approx-
imately 6% GABAergic neurons58, these will exert a strong inhibitory control over excitatory neurotransmis-
sion within the cultures. Indeed, application of GABAergic antagonists has been used to mimic epileptiform-like 
activity in hippocampal cultures59,60, hence the inhibition of GABAergic neuronal iring by TTX in the perfused 
chamber would result in the increased activity in the naïve chamber due to decreased GABAergic tone extending 
from the perfused to the naïve chamber. Furthermore, glutamate induced increases in neuronal activity were 
abolished during the co-application of glutamate and TTX, despite increases in intracellular calcium in neurons 
within the perfused chamber. Collectively, these results demonstrate that changes in neuronal activity within the 
naïve culture chamber are driven by functional, synaptic communication from neurons in the perfused chamber.
www.nature.com/scientificreports/
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We have developed a novel platform that integrates microluidic perfusion and Ca2+ imaging techniques for 
studying neuromodulation and synaptic connectivity between primary hippocampal cultures. We show that both 
direct neuronal excitability and the consequent synaptic communication between synaptically connected but 
environmentally isolated cultures can be simultaneously monitored, providing hundreds of readouts from each 
device. In addition, with the recent surge in interest in the use of human stem cell derived neurons to investigate 
CNS disorders61,62, the platform described in the present study may ofer new avenues to examine the underlying 
causes of CNS disease and allow potential novel therapeutics to be tested in a cost-efective, miniaturised manner.
Ǥ Access to all data underpinning this publication is restricted to a request only basis. 
More information and contact details are available from the University of Strathclyde at http://dx.doi.
org/10.15129/5a018c9b-9458-4e3f-8a92-23657abcd44e. 
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